Patents Assigned to Seattle Genetics, Inc.
  • Humanized anti-CD70 binding agents and uses thereof
    Patent number: 9701752
    Abstract: Disclosed are CD70 binding agents, such as humanized anti-CD70 antibodies and fragments and derivatives, that exert a cytotoxic, cytostatic or immunomodulatory on CD70 expressing cells, as well as pharmaceutical compositions and kits comprising the antibody, fragment or derivative. Also disclosed are methods for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the CD70 binding agents or pharmaceutical compositions.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: July 11, 2017
    Assignee: Seattle Genetics, Inc.
    Inventors: Charlotte McDonagh, Paul Carter
  • BETA-GLUCURONIDE-LINKER DRUG CONJUGATES
    Publication number: 20170189542
    Abstract: Ligand Drug conjugate compounds comprising a ?-glucuronide-based linker and methods of using such compounds are provided.
    Type: Application
    Filed: March 20, 2017
    Publication date: July 6, 2017
    Applicant: SEATTLE GENETICS, INC.
    Inventor: Scott Jeffrey
  • BETA-GLUCURONIDE-LINKER DRUG CONJUGATES
    Publication number: 20170189540
    Abstract: Ligand Drug conjugate compounds comprising a ?-glucuronide-based linker and methods of using such compounds are provided.
    Type: Application
    Filed: September 25, 2013
    Publication date: July 6, 2017
    Applicant: Seattle Genetics, Inc.
    Inventor: Scott Jeffrey
  • OPTIMAL DOSING OF A CD19-ANTIBODY DRUG CONJUGATE
    Publication number: 20170182178
    Abstract: Methods of optimal dosing of CD19-antibody drug conjugates are disclosed.
    Type: Application
    Filed: April 7, 2015
    Publication date: June 29, 2017
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Baiteng ZHAO, Tina ALBERTSON, Tae HAN
  • PREPARING ANTIBODIES FROM CHO CELL CULTURES FOR CONJUGATION
    Publication number: 20170159099
    Abstract: The invention is based in part on the observation that a CHO cell oxidizing enzyme, particularly QSOX1, can survive a seemingly rigorous antibody purification process to reduce subsequent conjugation efficiency of the antibody to a drug. Whether the oxidizing enzyme survives the purification procedure depends on which purification techniques are employed which can vary from one antibody to another. With knowledge that contamination with a CHO cell oxidizing enzyme is a potential problem for subsequent conjugation, a suitable purification scheme can be devised for any antibody that eliminates or at least reduces CHO oxidizing enzyme(s) to an acceptable level.
    Type: Application
    Filed: November 21, 2014
    Publication date: June 8, 2017
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Kevin Beam, Damon Meyer, Bradley Hayes, Robert Lyon, John Valliere-Douglass
  • DOSAGE AND ADMINISTRATION OF NON-FUCOSYLATED ANTI-CD40 ANTIBODIES
    Publication number: 20170137528
    Abstract: This invention relates methods of using a non-fucosylated anti-CD40 antibody for treatment of cancer and chronic infectious diseases.
    Type: Application
    Filed: January 20, 2017
    Publication date: May 18, 2017
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Shyra Gardai, Che-Leung Law, Stanford Peng, Jing Yang, Haley Neff-LaFord, Thomas John Manley
  • Cyclodextrin and antibody-drug conjugate formulations
    Patent number: 9610361
    Abstract: Disclosed are formulations, including both liquid and lyophilized formulations, comprising a benzodiazepine anti-body-drug conjugate (ADC) and a cyclodextrin. Also disclosed are methods of purifying mixtures comprising benzodiazepine anti-body-drug conjugates and process drug-related impurities.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: April 4, 2017
    Assignee: Seattle Genetics, Inc.
    Inventors: Hui Li, Shan Jiang, Mary Wallace, Damon Meyer
  • Targeted pyrrolobenzodiazapine conjugates
    Patent number: 9592240
    Abstract: Provided are Conjugate comprising PBDs conjugated to a targeting agent and methods of using such PBDs.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: March 14, 2017
    Assignees: SEATTLE GENETICS INC., MEDIMMUNE LIMITED
    Inventors: Philip Wilson Howard, Scott Jeffrey, Patrick Burke, Peter Senter
  • CD33 antibodies and use of same to treat cancer
    Patent number: 9587019
    Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD33. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting CD33.
    Type: Grant
    Filed: May 15, 2013
    Date of Patent: March 7, 2017
    Assignee: SEATTLE GENETICS, INC.
    Inventors: May Kung Sutherland, Maureen Ryan, Django Sussman, Patrick Burke, Scott Jeffrey
  • METHODS OF INHIBITION OF PROTEIN FUCOSYLATION IN VIVO USING FUCOSE ANALOGS
    Publication number: 20170035790
    Abstract: The invention provides methods and compositions for the inhibition of fucosylation of proteins, including antibodies, in vivo by administration of a fucose analog.
    Type: Application
    Filed: October 21, 2016
    Publication date: February 9, 2017
    Applicant: Seattle Genetics, Inc.
    Inventors: Peter Senter, Stephen Alley, Dennis Benjamin
  • STABLE FORMULATIONS FOR ANTI-CD19 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
    Publication number: 20170028062
    Abstract: This disclosure provides optimized formulations for CD19 antibodies and antibody-drug conjugates (ADCs)
    Type: Application
    Filed: April 7, 2015
    Publication date: February 2, 2017
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Kent Amsberry, Shan Jiang
  • Pyrrolobenzodiazepines and targeted conjugates
    Patent number: 9526798
    Abstract: A compound, or a pharmaceutically acceptable salt or solvate thereof, or conjugates thereof, selected from the group consisting of formula wherein: (a) R10 is H, and R11 is OH, ORA, where RA is saturated C1-4 alkyl; (b) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (c) R10 is H and R11 is S02M, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation, or both M together are a divalent pharmaceutically acceptable cation.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: December 27, 2016
    Assignees: SEATTLE GENETICS, INC., MEDIMMUNE LIMITED
    Inventors: Scott Jeffrey, Patrick Burke, Philip Wilson Howard
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS
    Publication number: 20160369003
    Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: March 30, 2016
    Publication date: December 22, 2016
    Applicants: AGENSYS, INC., Seattle Genetics, Inc.
    Inventors: Robert Kendall MORRISON, Zili AN, Karen Jane Meyrick MORRISON, Josh SNYDER, Xiao-Chi JIA
  • Methods of using monomethylvaline compositions having phenylalanine carboxy modifications at the C-terminus
    Patent number: 9522194
    Abstract: Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) having a carboxylic acid equivalent at the C-terminal phenylalanine were prepared and attached to ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand-drug conjugates were active in vitro and in vivo in inhibiting cell proliferation and are represented by the general structure of Lv-[(LU)0-1-(D)1-4]p wherein L- is Ligand unit; LU is a Linker unit (LU); v is 1; p is an number ranging from about 1 to about 20; and D is a drug moiety having the formula: wherein the moiety —N(R9)Z1 is a phenylalanine bioisostere, wherein Z1 is —CH(R10)Z2 so that the phenylalanine bioisostere has the structure of Formula A: and wherein the substituents R2-R10, X1 and Z2 are as defined.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: December 20, 2016
    Assignee: Seattle Genetics, Inc.
    Inventors: Svetlana O Doronina, Toni Beth Kline, Scott Jeffrey, Peter D Senter, Damon Meyer
  • Self-stabilizing linker conjugates
    Patent number: 9504756
    Abstract: The present invention provides Ligand-Drug Conjugates, Drug-Linkers, Linkers, and Ligand-Linker Conjugates comprising a self-stabilizing linker assembly component.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: November 29, 2016
    Assignee: Seattle Genetics, Inc.
    Inventors: Robert Lyon, Svetlana O. Doronina, Timothy Bovee
  • Methods of inhibition of protein fucosylation in vivo using fucose analogs
    Patent number: 9504702
    Abstract: The invention provides methods and compositions for the inhibition of fucosylation of proteins, including antibodies, in vivo by administration of a fucose analog.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: November 29, 2016
    Assignee: Seattle Genetics, Inc.
    Inventors: Peter Senter, Stephen Alley, Dennis Benjamin
  • Antibodies to integrin AVB6 and use of same to treat cancer
    Patent number: 9493566
    Abstract: The invention provides antibodies that specifically bind to integrin ?v?6. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting ?v?6.
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: November 15, 2016
    Assignee: Seattle Genetics, Inc.
    Inventors: Maureen Ryan, Sussman Django
  • PEGYLATED DRUG-LINKERS FOR IMPROVED LIGAND-DRUG CONJUGATE PHARMACOKINETICS
    Publication number: 20160310612
    Abstract: The present invention provides Ligand-Drug Conjugates comprising a PEG Unit in a parallel orientation to the Drug Unit. The invention provides inter alia, Ligand-Drug Conjugates (LDCs), methods of preparing and using them, and intermediates thereof. The Ligand-Drug Conjugates are stable in circulation, yet capable of inflicting cell death on targeted cells or inhibiting proliferation of targeted cells once its drug cargo is released in the vicinity or within targeted cells. In principle embodiments, an LDC of the present invention is represented by the structure of Formula I.
    Type: Application
    Filed: October 14, 2014
    Publication date: October 27, 2016
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Robert Lyon, Patrick Burke, Joshua Hunter
  • Auristatin drug linker conjugates
    Patent number: 9463252
    Abstract: Drug Linker compounds and Drug Linker Ligand conjugates are provided that have auristatins linked via the C-terminus. The conjugates show efficacy without the need for a self-immolative group to release the drug.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: October 11, 2016
    Assignee: Seattle Genetics, Inc.
    Inventors: Peter Senter, Svetlana Doronina, Timothy Bovee
  • Activated carbon filtration for purification of benzodiazepine ADCs
    Patent number: 9453046
    Abstract: Disclosed are methods of purifying mixtures comprising benzoidiazepine antibody-drug conjugates.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: September 27, 2016
    Assignee: Seattle Genetics, Inc.
    Inventors: Damon Meyer, Michael Sun